ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.
|Articles|July 14, 2009
- ONCOLOGY Vol 23 No 8
- Volume 23
- Issue 8
US Oncology Launches Oncology-Specific EHR
US Oncology, Inc, announced the launch of iKnowMed-an oncology-specific electronic health record (EHR) system designed by oncologists for oncologists-to the open market.
Advertisement
US Oncology, Inc, announced the launch of iKnowMed-an oncology-specific electronic health record (EHR) system designed by oncologists for oncologists-to the open market. Features of iKnowMed include oncology-specific terminology, decision support, outcomes reporting, and imaging reports.
Articles in this issue
about 17 years ago
Resolving Confusion: The New Realities of Mantle Cell Lymphomaabout 17 years ago
Reishi Mushroomabout 17 years ago
Unraveling the Mystery of a Supraclavicular Massabout 17 years ago
Management of Relapsed Mantle Cell Lymphoma: Still a Treatment Challengeabout 17 years ago
Effective Local Therapy and Long-Term Survival in Breast Cancerabout 17 years ago
Local Therapy MattersAdvertisement
Related to this article
Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5